Pharmacy & Therapeutics - September 2008 - (Page 531)

DRUG FORECAST II clinical trial of ixabepilone (BMS247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726–2734. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS247550), an epothilone B analog, as firstline therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415–3420. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421–3427. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (San Antonio Breast Cancer Symposium, Abstract 305). Breast Cancer Res Treat 2005; 94(Suppl 1). Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epo thilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25: 63–67. Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts (American Society of Clinical Oncology meeting, Abstract 12017). J Clin Oncol 2006;24(Suppl 18S). Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210–5217. Vahdat L, Klimovsky J, Bunnell C. Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data (American Society of Clinical Oncology meeting, Abstract 1006). J Clin Oncol 2006;24(Suppl 18S). Bunnell C, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline (American Society of Clinical Oncology meeting, Abstract 10511). J Clin Oncol 2006; 24(Suppl 18S). Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non–small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448–3455. Burtness B, Goldwasser MA, Axelrod R, et al. A randomized phase II study of BMS-247550 (ixabepilone) given daily × 5 days ever y 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck (American Society of Clinical Oncology meeting, Abstract 5532). J Clin Oncol 2006;24(Suppl 18S). Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractor y hormonerefractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556–563. Liu G, Wang W, Dipaola R, et al. A phase II study of a weekly schedule of BMS247550 for patients with hormone-refractory prostate cancer: A trial of the Easter n Cooperative Oncology Group (E3803) (American Society of Clinical Oncology meeting, Abstract 4618). J Clin Oncol 2007;24(Suppl 18S). Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapynaive patients with hormone-refractory prostate cancer: A Southwest Oncology Group trial S0111. J Clin Oncol 2005;23: 8724–8729. Dreicer R, Li S, Manola J, et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group. Cancer 2007;110:759–763. Zhuang SH, Menefee M, Kotz H, et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer (American Society of Clinical Oncology meeting, Abstract 4550). J Clin Oncol 2004;22(Suppl 14S). Feldman DR, Kondagunta GV, Ginsberg MS, et al. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 2007;25: 487–490. Whitehead RP, McCoy S, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest New Drugs 2006;24:515–520. Ajani JA, Safran H, Bokemeyer C, et al. A multicenter phase II study of BMS247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006;24:441–446. Singh DA, Taber D, Ansari R, et al. A phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer (HBC): An updated analysis (American Society of Clinical Oncology meeting, Abstract 14050). J Clin Oncol 2006;24(Suppl 18S). Smith SM, Pro B, van Besien K, et al. A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas (American Society of Clinical Oncology meeting, Abstract 6625). J Clin Oncol 2005;23(Suppl 16S). O’Connor O, Straus D, Moskowitz C, et al. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in ver y drug resistant disease (American Society of Clinical Oncology meeting, Abstract 6569). J Clin Oncol 2005;23(Suppl 16S). Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25: 1082–1088. Takimoto CH, Liu PY, Lenz H, et al. A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550), in patients with advanced malignancies and var ying degrees of hepatic impairment: A Southwest Oncology Group Early Therapeutics Committee and NCI Organ Dysfunction Working Group trial (American Society of Clinical Oncology meeting, Abstract 2004). J Clin Oncol 2006;24(Suppl 18S). Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2003;2:141– 146. Lenz HJ. Management and preparedness for infusion and hypersensitivity re actions. Oncologist 2007;12:601–609. Goel S, Goldberg G, Iacono LC, et al. Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone (American Society of Clinical Oncology meeting, Abstract 2005). J Clin Oncol 2006;24(Suppl 18S). Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 2007;25:3389–3391. ClinicalTrials.gov: a service of the U.S. National Institutes of Health. Available at: www.clinicaltrials.gov. Accessed October 2007. Academy of Managed Care Pharmacy (AMCP). Formulary Dossier for Ixempra (ixabepilone). November 2007. I 49. 39. 60. 50. 61. 40. 41. 51. 62. 42. 52. 63. 64. 43. 53. 65. 66. 54. 44. 67. 55. 45. 56. 46. 57. 47. 58. 48. 59. Vol. 33 No. 9 • September 2008 • P&T® 531 http://www.clinicaltrials.gov http://www.clinicaltrials.gov

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - September 2008

Pharmacy & Therapeutics - September 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications Vaccine Declinations Present New Challenges for Public Health Universal Health Care in America Digestive Disease Week and American Diabetes Association Pharmaceutical Approval Update

Pharmacy & Therapeutics - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.